Gram-scale preparation of the antibiotic lead compound salicyl-AMS, a potent inhibitor of bacterial salicylate adenylation enzymes. Academic Article uri icon

Overview

abstract

  • Salicyl-AMS (1) is a potent inhibitor of salicylate adenylation enzymes used in bacterial siderophore biosynthesis and a promising lead compound for the treatment of tuberculosis. An optimized, multigram synthesis is presented, which provides salicyl-AMS as its sodium salt (1·Na) in three synthetic steps followed by a two-step salt formation process. The synthesis proceeds in 11.6% overall yield from commercially available adenosine 2',3'-acetonide and provides highly purified material.

publication date

  • May 5, 2020

Research

keywords

  • Anti-Bacterial Agents
  • Mycobacterium tuberculosis

Identity

PubMed Central ID

  • PMC7367610

Scopus Document Identifier

  • 85084451355

Digital Object Identifier (DOI)

  • 10.1021/ol0617289

PubMed ID

  • 32416922

Additional Document Info

volume

  • 638